ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Cortexyme raises $76 million to test bacterial protease inhibitor in Alzheimer’s

by Ryan Cross
June 3, 2018 | APPEARED IN VOLUME 96, ISSUE 23

 

South San Francisco-based Cortexyme has raised $76 million to fund a unique approach to treating Alzheimer’s disease. Cortexyme was cofounded by University of California, San Francisco, psychiatrist Stephen Dominy, who discovered bacteria and accumulations of a bacterial protease in the brains of people with Alzheimer’s. The start-up developed a small-molecule inhibitor of this protease and will begin testing it in a Phase II trial next year. New investors for the series B financing include Sequoia Capital, Vulcan Capital, and Verily Life Sciences. Returning investors include Pfizer and Takeda Ventures.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment